| Trial ID: | L3512 |
| Source ID: | NCT00513214
|
| Associated Drug: |
Xoma 052
|
| Title: |
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: XOMA 052|DRUG: Placebo
|
| Outcome Measures: |
Primary: Safety assessed by pre- and post-treatment serial measurements of vital signs., Part 1: Day 0 pre-treatment through Day 56. Part 2: Day 0 pre-treatment through Day 56. Part 3: Day 0 pre-treatment through Day 84.|Safety assessed by treatment-emergent adverse events., Part 1: Day 0 post-treatment through Day 56. Part 2: Day 0 post-treatment through Day 56. Part 3: Day 0 post-treatment through Day 84. |
|
| Sponsor/Collaborators: |
Sponsor: XOMA (US) LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
68
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-07
|
| Completion Date: |
2010-02
|
| Results First Posted: |
|
| Last Update Posted: |
2011-10-04
|
| Locations: |
Escondido, California, 92026, United States|Miami Gardens, Florida, 33169, United States|Omaha, Nebraska, 68154, United States|San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00513214
|
